"The possible implication of endothelin in the pathology of COVID-19-induced pulmonary hypertension".
Pulm Pharmacol Ther
; 71: 102082, 2021 12.
Article
in English
| MEDLINE | ID: covidwho-1492538
ABSTRACT
COVID-19 pandemic has changed the world dramatically since was first reported in Wuhan city, China [1]. Not only as a respiratory illness that could lead to fatal respiratory failure, but also some evidences suggest that it can propagate as a chronic disease associated with a variety of persistent post COVID-19 pathologies that affect patients' life [2,3]. Pulmonary hypertension (PH) is one of the challenging diseases that may develop as a consequence of SARS-COV-2 infection in some COVID-19 survivors [4,5]. The vasopressor, proliferative, proinflammatory, and prothrombotic actions of endothelin [6] may be encountered in the COVID-19-induced PH pathology. And so, endothelin blockers may have an important role to restrict the development of serious PH outcomes with special precautions considering patients with significant hypoxemia.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Endothelins
/
COVID-19
/
Hypertension, Pulmonary
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Pulm Pharmacol Ther
Journal subject:
Pharmacology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS